FDA Approves Lilly’s Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company – Investors | Eli Lilly and Company

by

  1. FDA Approves Lilly’s Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company Investors | Eli Lilly and Company
  2. Lilly’s bowel disease drug gets US FDA nod for treatment in adults Reuters
  3. FDA approves Eli Lilly ulcerative colitis treatment Omvoh – STAT STAT
  4. FDA Approves Lilly’s Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire
  5. FDA Approves Lilly’s Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

Leave a Comment